Literature DB >> 20592492

Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.

Peng Li1, Scott A Waldman.   

Abstract

Colon cancer, the second leading cause of cancer-related mortality worldwide, originates from the malignant transformation of intestinal epithelial cells. The intestinal epithelium undergoes a highly organized process of rapid regeneration along the crypt-villus axis, characterized by proliferation, migration, differentiation and apoptosis, whose coordination is essential to maintaining the mucosal barrier. Disruption of these homeostatic processes predisposes cells to mutations in tumor suppressors or oncogenes, whose dysfunction provides transformed cells an evolutionary growth advantage. While sequences of genetic mutations at different stages along the neoplastic continuum have been established, little is known of the events initiating tumorigenesis prior to adenomatous polyposis coli (APC) mutations. Here, we examine a role for the corruption of homeostasis induced by silencing novel tumor suppressors, including the intestine-specific transcription factor CDX2 and its gene target guanylyl cyclase C (GCC), as early events predisposing cells to mutations in APC and other sequential genes that initiate colorectal cancer. CDX2 and GCC maintain homeostatic regeneration in the intestine by restricting cell proliferation, promoting cell maturation and adhesion, regulating cell migration and defending the intestinal barrier and genomic integrity. Elimination of CDX2 or GCC promotes intestinal tumor initiation and growth in aged mice, mice carrying APC mutations or mice exposed to carcinogens. The roles of CDX2 and GCC in suppressing intestinal tumorigenesis, universal disruption in their signaling through silencing of hormones driving GCC, and the uniform overexpression of GCC by tumors underscore the potential value of oral replacement with GCC ligands as targeted prevention and therapy for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20592492      PMCID: PMC3040833          DOI: 10.4161/cbt.10.3.12539

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  79 in total

1.  p53 sends nucleotides to repair DNA.

Authors:  G Lozano; S J Elledge
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

Review 2.  Stem cells: the intestinal stem cell as a paradigm.

Authors:  S P Bach; A G Renehan; C S Potten
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

3.  Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays.

Authors:  D A Notterman; U Alon; A J Sierk; A J Levine
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

4.  Progressive changes in adherens junction structure during intestinal adenoma formation in Apc mutant mice.

Authors:  A M Carothers; K A Melstrom; J D Mueller; M J Weyant; M M Bertagnolli
Journal:  J Biol Chem       Date:  2001-08-01       Impact factor: 5.157

5.  Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal.

Authors:  W C Yang; J Mathew; A Velcich; W Edelmann; R Kucherlapati; M Lipkin; K Yang; L H Augenlicht
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

6.  Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2.

Authors:  J Park; S Schulz; S A Waldman
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

7.  Telomere dysfunction and evolution of intestinal carcinoma in mice and humans.

Authors:  K L Rudolph; M Millard; M W Bosenberg; R A DePinho
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

8.  A role for the Adenomatous Polyposis Coli protein in chromosome segregation.

Authors:  K B Kaplan; A A Burds; J R Swedlow; S S Bekir; P K Sorger; I S Näthke
Journal:  Nat Cell Biol       Date:  2001-04       Impact factor: 28.824

9.  Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers.

Authors:  R B Halberg; D S Katzung; P D Hoff; A R Moser; C E Cole; R A Lubet; L A Donehower; R F Jacoby; W F Dove
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

10.  The homeobox gene CDX2 in colorectal carcinoma: a genetic analysis.

Authors:  S Sivagnanasundaram; I Islam; I Talbot; F Drummond; J R Walters; Y H Edwards
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

View more
  6 in total

1.  Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases.

Authors:  Heather N Tinsley; Gary A Piazza
Journal:  Curr Colorectal Cancer Rep       Date:  2012-12

2.  Detection of circulating tumor cells in peripheral blood of colorectal cancer patients without distant organ metastases.

Authors:  Yong Liu; Jun Qian; Jian-Guo Feng; Hai-Xing Ju; Yu-Ping Zhu; Hai-Yang Feng; De-Chuan Li
Journal:  Cell Oncol (Dordr)       Date:  2012-11-14       Impact factor: 6.730

3.  GUCY2C: at the intersection of obesity and cancer.

Authors:  Gilbert W Kim; Jieru E Lin; Scott A Waldman
Journal:  Trends Endocrinol Metab       Date:  2013-01-29       Impact factor: 12.015

Review 4.  Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase C.

Authors:  Philipp R Weiglmeier; Paul Rösch; Hanna Berkner
Journal:  Toxins (Basel)       Date:  2010-08-26       Impact factor: 4.546

Review 5.  Review article: Linaclotide for the management of irritable bowel syndrome with constipation.

Authors:  P Layer; V Stanghellini
Journal:  Aliment Pharmacol Ther       Date:  2014-01-16       Impact factor: 8.171

6.  Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity.

Authors:  Amanda M Pattison; Joshua R Barton; Ariana A Entezari; Alicja Zalewski; Jeff A Rappaport; Adam E Snook; Scott A Waldman
Journal:  Cancer Biol Ther       Date:  2020-06-28       Impact factor: 4.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.